

Glanbia plc Transaction in Own Shares

Glanbia plc ("Glanbia" or the "Company"), the Global Nutrition Group, announces that on Tuesday, 29 August, 2023 it purchased the following number of its ordinary shares (the "Ordinary Shares") on Euronext Dublin, via Glanbia's broker J&E Davy. The Ordinary Shares purchased will be cancelled.

	Euronext Dublin
Number of Ordinary Shares purchased	60,000
Highest price paid per Ordinary Share	€15.5000
Lowest price paid per Ordinary Share	€15.4400
Volume weighted average price paid per Ordinary Share	€15.4500

The Ordinary Shares purchased form part of Glanbia's intention to buy back the Company's Ordinary Shares of a total value of up to €100 million in the period up to 30 September 2023 ("Buy-Back Programme"). This Buy-Back Programme was originally announced on 1 March 2023 for a value of up to €50 million and formally commenced on that date. An incremental buyback amount of up to €50 million was announced on 4 May 2023.

Following settlement of the above transactions and subsequent share cancellation Glanbia will hold 265,648,237 ordinary shares in issue.

In accordance with Article 5(1)(b) of Regulation (EU) No 596/2014 (the Market Abuse Regulation), a detailed breakdown of individual trades made by Davy on behalf of Glanbia as part of the buyback programme is scheduled to this announcement.

Contact:

Liam Hennigan
Group Secretary and Head of
Investor Relations
Tel: 00 353 86 046 8375

Olivia Kennington
Deputy Group Secretary
Tel: 00 35356 777 2200

Issuer name:	Glanbia plc
LEI	635400SRMCBHVMSKJS84
ISIN:	IE0000669501
Intermediary name:	J&E Davy
Intermediary code:	DAVYIE21
Time zone:	GMT
Currency:	EUR

Aggregated Information

Trading venue	Currency	Volume Weighted Average Price	Aggregated volume
Euronext Dublin	EUR	€15.4500	60,000

Number of Shares	Price per Share (EUR)	Trading Venue	Time of Transaction	MatchId
50000	15.44	10:22:50	Euronext Dublin	00040859780TRLO0-1
10000	15.5	13:00:11	Euronext Dublin	00040861313TRLO0-1

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact ms@seg.com or visit www.ms.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our [Privacy Policy](#).

END

POSBLGDIUDDGXC